These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

How could higher U.S. tariffs on Indian pharmaceutical products impact drug stocks? Seeking Alpha analysts weigh in. Read ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and ...

Adverse events reported in oncology clinical trials don’t always match what patients experience. What is behind this ...

Health-care company shares rose with the broader rebound in stocks as investors increasingly expect a rate cut from the Federal Reserve.

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...